Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.
Wong JK, Lim HJ, Tam VC, Burak KW, Dawson LA, Chaudhury P, Abraham RJ, Meyers BM, Sapisochin G, Valenti D, Samimi S, Ramjeesingh R, Mujoomdar A, Martins I, Dixon E, Segedi M, Liu DM. Wong JK, et al. Among authors: tam vc. Cancer Treat Rev. 2023 Apr;115:102526. doi: 10.1016/j.ctrv.2023.102526. Epub 2023 Mar 2. Cancer Treat Rev. 2023. PMID: 36924644 Review.
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database.
Samawi HH, Sim HW, Chan KK, Alghamdi MA, Lee-Ying RM, Knox JJ, Gill P, Romagnino A, Batuyong E, Ko YJ, Davies JM, Lim HJ, Cheung WY, Tam VC; CHORD Consortium. Samawi HH, et al. Among authors: tam vc. Cancer Med. 2018 Jul;7(7):2816-2825. doi: 10.1002/cam4.1493. Epub 2018 May 15. Cancer Med. 2018. PMID: 29766659 Free PMC article.
Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019.
Lee-Ying R, Ahmed O, Ahmed S, Ahmed S, Bathe OF, Brunet B, Dawson L, Davies J, Gordon V, Hebbard P, Kasnik J, Kim CA, Le D, Lee MKC, Lim H, McGhie JP, Mulder K, Park J, Renouf D, Tam V, Visser R, Wong RPW, Zaidi A, Doll C. Lee-Ying R, et al. Curr Oncol. 2021 Sep 21;28(5):3629-3648. doi: 10.3390/curroncol28050310. Curr Oncol. 2021. PMID: 34590606 Free PMC article.
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Fung AS, et al. Among authors: tam vc. Cancer Med. 2020 Jul;9(13):4640-4647. doi: 10.1002/cam4.3116. Epub 2020 May 7. Cancer Med. 2020. PMID: 32378799 Free PMC article.
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Alghamdi MA, Amaro CP, Lee-Ying R, Sim HW, Samwi H, Chan KK, Knox JJ, Ko YJ, Swiha M, Batuyong E, Romagnino A, Cheung WY, Tam VC; Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium. Alghamdi MA, et al. Among authors: tam vc. Cancer Med. 2020 Jul;9(14):4918-4928. doi: 10.1002/cam4.3228. Epub 2020 Jun 11. Cancer Med. 2020. PMID: 32529797 Free PMC article.
68 results